Lantheus Holdings Inc
NASDAQ:LNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lantheus Holdings Inc
Net Income (Common)
Lantheus Holdings Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Net Income (Common)
$233.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Figs Inc
NYSE:FIGS
|
Net Income (Common)
$34.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Net Income (Common)
$175.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Net Income (Common)
$732k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-62%
|
CAGR 10-Years
-34%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Net Income (Common)
$410.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
11%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Net Income (Common)
$128.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
Lantheus Holdings Inc
Glance View
Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.
See Also
What is Lantheus Holdings Inc's Net Income (Common)?
Net Income (Common)
233.6m
USD
Based on the financial report for Dec 31, 2025, Lantheus Holdings Inc's Net Income (Common) amounts to 233.6m USD.
What is Lantheus Holdings Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
103%
Over the last year, the Net Income (Common) growth was -25%. The average annual Net Income (Common) growth rates for Lantheus Holdings Inc have been 103% over the past three years .